Michela Luciano, PhD, is a science writer and molecular biologist with academic and research background in oncology and immunology. She holds a PhD from the University of Salzburg, where she was part of the Immunity in Cancer and Allergy doctoral program. Her work has contributed to multiple peer-reviewed publications in international journals, with a focus on inflammation, leukemogenesis, and molecular pathways involved in acute myeloid leukemia. With a passion for clear and impactful scientific communication, she transitioned into science writing in 2022, taking on her first role as a science writer. In 2025, she joined Bionews, where she continues to translate complex biomedical research into accessible content. She is a member of the European Medical Writers Association and continually pursues opportunities to grow and enhance her expertise in science communication.

Education

• PhD in Biosciences and Medical Biology, University of Salzburg, Austria (2017–2022), Doctoral Program: Immunity in Cancer and Allergy (ICA)
• MSc in Medical Biotechnology, University of L’Aquila, Italy (2011–2014)
• BSc in Biotechnology, University of L’Aquila, Italy (2006–2011)

Certifications

• 2023 – Editing and Proofreading Essentials, EMWA

Professional Organizations and Affiliations

• European Medical Writers Association (EMWA) – Member since 2023

Published Works

• Sieberer H, Luciano M, et al. Inhibition of NLRP3 enhances pro-apoptotic effects of FLT3 inhibition in AML. Cell Communication and Signaling. 2025;23(1):53. DOI:10.1186/s12964-025-02046-w. PMID:38864235.
• Luciano M, et al. Targeting NLRP3 inhibits AML progression by inducing PERK/eIF2-mediated apoptosis. Cell Communication and Signaling. 2024;22(1):424. DOI:10.1186/s12964-024-01777-6. PMID:39223663.
• Blöchl C, Holzner C, Luciano M, et al. Proteolytic profiling of Streptococcal Pyrogenic Exotoxin B (SpeB) by complementary HPLC-MS approaches. International Journal of Molecular Sciences. 2022;23(1):412. DOI:10.3390/ijms23010412. PMID:35055459.
• Luciano M, Krenn PW, Horejs-Hoeck J. The cytokine network in acute myeloid leukemia. Frontiers in Immunology. 2022;13:1000996. DOI:10.3389/fimmu.2022.1000996. PMC9554002. PMID:36248849.
• Urwanisch L, Luciano M, Horejs-Hoeck J. The NLRP3 inflammasome and its role in the pathogenicity of leukemia. International Journal of Molecular Sciences. 2021;22(3):1271. DOI:10.3390/ijms22031271. PMC7865748. PMID:33525345.
• Binder S, Luciano M, Horejs-Hoeck J. The cytokine network in acute myeloid leukemia (AML): A focus on pro- and anti-inflammatory mediators. Cytokine & Growth Factor Reviews. 2018;43:8–15. DOI:10.1016/j.cytogfr.2018.08.004. PMID:30181021.

At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.